Practice
Featured experience
Chime $993.6 million IPO
The shares are listed on the Nasdaq Global Select Market
Cipher Mining 300 MW, $5.5 billion lease agreement with Amazon Web Services
We advised Cipher Mining on the transaction
Diameter Capital Partners $4.5 billion fundraise for its third dislocation fund
We advised Diameter on the transaction
Banco Santander $12.2 billion acquisition of Webster Bank
We are advising Banco Santander on the transaction
Westlake Chemical $300 million notes offering
Davis Polk advised the representatives of the underwriters on an SEC-registered offering by Westlake Chemical…
Aptiv $2.2 billion ordinary share and mandatory convertible preferred offerings
Davis Polk advised Aptiv PLC in connection with a $1.1 billion SEC-registered offering of 15,149,519 ordinary shares (which…
Westlake Chemical $300 million notes offering
Davis Polk advised the representatives of the underwriters on an SEC-registered offering by Westlake Chemical…
Westlake Chemical $300 million notes offering
Davis Polk advised the representatives of the underwriters on an SEC-registered offering by Westlake Chemical…
Mohawk Capital Finance €500 million notes offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Mohawk Capital Finance S.A. of…
Aptiv $2.2 billion ordinary share and mandatory convertible preferred offerings
Davis Polk advised Aptiv PLC in connection with a $1.1 billion SEC-registered offering of 15,149,519 ordinary shares (which…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…
Bank of N.T. Butterfield & Son $100 million subordinated notes offering
Davis Polk advised the sole book-running manager in connection with an offering by The Bank of N.T. Butterfield & Son…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…
Jazz Pharmaceuticals $850 million exchangeable senior notes offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…